Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | NMT2 | O60551 | 1/20 | 0.38 |
| ▸ | NMT1 | P30419 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | PGA5 | P0DJD9 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23071799 | 0.85 | NMT2 (0.45) | CASP1NMT2NMT1CTSL | |
| SCHEMBL23433104 | 0.84 | PGA5 (0.34) | HDAC1HDAC6PGA5 | |
| SCHEMBL23071834 | 0.84 | NMT2 (0.42) | CPB2CASP1NMT2NMT1CTSL | |
| SCHEMBL23071999 | 0.83 | HDAC1 (0.38) | HDAC1HDAC6CASP1CTSL | |
| SCHEMBL23433135 | 0.82 | PGA5 (0.35) | PGA5 | |
| SCHEMBL23071959 | 0.81 | PGA5 (0.41) | CASP1NMT2NMT1CTSLPGA5 | |
| SCHEMBL23433153 | 0.81 | PGA5 (0.41) | CASP1NMT2NMT1CTSLPGA5 | |
| SCHEMBL24380518 | 0.81 | CTSS (0.37) | HDAC1HDAC6CPB2CASP1NMT2 | |
| SCHEMBL23071837 | 0.80 | FAAH (0.46) | CASP1NMT2NMT1CTSL | |
| SCHEMBL23071880 | 0.80 | PGA5 (0.34) | HDAC1HDAC6PGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210163458-A1 | NOVEL CRYPTOPHYCIN COMPOUNDS AND CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI SA (FR) | 2021-06-03 | — | — | US | disclosed |
| US-10941139-B2 | Cryptophycin compounds and conjugates, their preparation and their therapeutic use | SANOFI (FR) | 2021-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163458-A1 | NOVEL CRYPTOPHYCIN COMPOUNDS AND CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | XPOT, HCCS, COIL | HDAC1 3617/4885HDAC6 320/4885CPB2 1160/4885 |
| US-10941139-B2 | Cryptophycin compounds and conjugates, their preparation and their therapeutic use | XPOT, COIL, HCCS | HDAC1 3570/4885HDAC6 489/4885CPB2 795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.